ESH EUROPEAN SCHOOL OF HAEMATOLOGY

10th Translational Research Conference
Myelodysplastic Syndromes, Overlap MDS/MPN Disorders and Clonal Haematopoiesis

October 16-18, 2026 - Malahide (Dublin), Ireland
Chairpersons: Pierre Fenaux, Katharina Götze, Mikkael Sekeres

Friday, October 16th, 2026

08:30–08:40 Welcome by chairpersons

SESSION I – Myelodysplastic syndromes and the march of clonal haematopoiesis
Chair: Mikkael Sekeres (Miami)

08:40-08:45	Introduction	Mikkael Sekeres (Miami)
08:45-09:00	The inexorable march of clonal evolution	Klaus Metzeler (Leipzig)
09:00-09:05	*Discussion*	
09:05-09:20	How do we define myelodysplastic syndromes progression?	Amy DeZern (Baltimore)
09:20-09:25	*Discussion*	
09:25-09:40	Where's the line between CCUS and myelodysplastic syndromes?	Nancy Gillis (Tampa)
09:40-09:45	*Discussion*	
09:45-09:52	Selected brief oral communication *ASXL1 mutation remodels the early hematopoietic proteome in myeloid neoplasms*	Christina Maria Perraki (Stockholm)
09:52-09:55	*Discussion*	
09:55-10:25	*Panel discussion*	

10:25-10:55 Coffee Break

SESSION II – The VEXAS nexus
Chair: Katja Sockel (Dresden)

10:55-11:00	Introduction	Katja Sockel (Dresden)
11:00-11:15	Genobiology of VEXAS	Olivier Kosmider (Paris)
11:15-11:20	*Discussion*	
11:20-11:35	Immune modulation and haematopoietic cell transplant in VEXAS syndrome	Emma Groarke (Bethesda)
11:35-11:40	*Discussion*	
11:40-11:55	Can we modify the natural history of VEXAS?	Thibault Comont (Toulouse)

11:55-12:00	*Discussion*	
12:00-12:07	Selected brief oral communication *Distinct Transcriptional Profiles of CD34+ Hematopoietic Cells in VEXAS Syndrome and Myelodysplastic Syndrome*	Marek Jedlicka (Prague)
12:07-12:10	*Discussion*	
12:10-12:40	*Panel discussion*	
12:40-14:25	***Lunch***	

SESSION III – Not another session on myelodysplastic syndromes classification and risk!
Chair: Pierre Fenaux (Paris)

14:25-14:30	Introduction	Pierre Fenaux (Paris)
14:30-14:45	The ICC and WHO classification: a marriage made in heaven	Robert Hasserjian (Boston)
14:45-14:50	*Discussion*	
14:50-15:05	Where the IPSSM succeeds and where it falls short	Aristoteles Giagounidis (Düsseldorf)
15:05-15:10	*Discussion*	
15:10-15:25	How artificial intelligence will transform classification and risk in myelodysplastic syndrome	Matteo Giovanni Della Porta (Milan)
15:25-15:30	*Discussion*	
15:30-15:37	Selected brief oral communication *JAK1/2 inhibition reprograms the CMML microenvironment by reversing immunosuppressive macrophage polarization despite MSC protection*	Manja Wobus (Dresden)
15:37-15:40	*Discussion*	
15:40-16:10	*Panel discussion*	
16:10-16:40	***Coffee break***	

SESSION IV – Special genetic populations
Chair: Michaela Fontenay (Paris)

16:40-16:45	Introduction	Michaela Fontenay (Paris)
16:45-17:00	The fault, dear Brutus, lies within ourselves: germline predisposition	Marie Sebert (Paris)
17:00-17:05	*Discussion*	
17:05-17:20	The Science of TP53	Francesc Solé (Barcelona)
17:20-17:25	*Discussion*	
17:25-17:40	Splicing factor mutations	Michaela Fontenay (Paris)
17:40-17:45	*Discussion*	

17:45-18:00	MDS/MPN overlap and CMML: overlooked in clinical trials….	Raphaël Itzykson (Paris)
18:00-18:05	*Discussion*	
18:05-18:12	Selected brief oral communication *Longitudinal single-cell multi-omics reveals selective remodeling of IDH-inhibitor-response methylation without eradicating stem-like IDH1-mutant clones*	Nuria A.Pizarroso (Paris)
18:12-18:15	*Discussion*	
18:15-18:45	*Panel discussion*	
18:50-20:20	**Mentored Poster Walk and Welcome Get Together** *Poster Walk leaders : Klaus Metzeler (Lepzig), Katja Sockel (Dresden)*	

Saturday, October 17th, 2026

09:00-10:00	**2 Simultaneous Meet the Expert sessions (non-clinical)**	
1.	NGS : Methods, interpretation of what is pathogenic and what is not, etc.	Klaus Metzeler (Leipzig)
2.	Quality of Life PROs	Fabio Efficace (Rome)
10:00-10:30	***Coffee break***	

SESSION V – Looking at myelodysplastic syndromes with a crystal ball
Chair: Valeria Santini (Florence)

10:30-10:35	Introduction	Valeria Santini (Florence)
10:35-10:50	Numbers and nuances in the epidemiology of myelodysplastic. syndromes	Nancy Gillis (Tampa)
10:50-10:55	*Discussion*	
10:55-11:10	Predicting response in lower- and higher-risk myelodysplastic syndromes	Valeria Santini (Florence)
11:10-11:15	*Discussion*	
11:15-11:30	Asking the patient about benefits of treatment in myelodysplastic syndromes	Fabio Efficace (Rome)
11:30-11:35	*Discussion*	
11:35-12:05	*Panel discussion*	
12:05-14:10	***Lunch***	

13:00-14:00 **IME SYMPOSIUM**
Treatment of higher-risk MDS prior to transplant
Chairs: Lionel Adès (Paris), Katharina Götze (Munich), Mikkael Sekeres (Miami)
Speakers: Klaus Metzeler (Leipzig), Guillermo Garcia-Manero (Houston)

This independent symposium is organised by ESH and funded by an educational grant from Jazz Pharmaceuticals. Jazz Pharmaceuticals are allowed no influence on the content of this symposium.

SESSION VI – Treating lower-risk myelodysplastic syndromes
Chair: Mikkael Sekeres (Miami)

14:10-14:15	Introduction	Mikkael Sekeres (Miami)
14:15-14:30	Upfront therapy for anemia in lower-risk myelodysplastic syndromes: the case for ESAs and the case for luspatercept	Eva Hellström-Lindberg (Stockholm)
14:30-14:35	*Discussion*	
14:35-14:50	Second-line therapies for lower-risk myelodysplastic syndromes	Sophie Park (Grenoble)
14:50-14:55	*Discussion*	
14:55-15:10	To all regulatory bodies: these should be the response criteria for lower-risk myelodysplastic syndromes!	Mikkael Sekeres (Miami)
15:10-15:15	*Discussion*	
15:15-15:30	The many faces of VEXAS: clinical manifestations	David Beck (New York)
15:30-15:35	*Discussion*	
15:35-15:42	Selected brief oral communication *Single-cell profiling of cellular states predicts lenalidomide response in lower-risk myelodysplastic syndromes*	Coen Veenstra (Amsterdam)
15:42-15:45	*Discussion*	
15:45-16:15	*Panel discussion*	
16:15-16:45	***Coffee break***	

SESSION VII – Treating higher-risk myelodysplastic syndromes
Chair: Amer Zeidan (New Haven)

16:45-16:50	Introduction	Amer Zeidan (New Haven)
16:50-17:05	Epigenetic dysregulation in myelodysplastic syndromes	Maria Figueroa (Miami)
17:05-17:10	*Discussion*	
17:10-17:25	The case for first-line therapies other than HMAs in higher-risk myelodysplastic syndromes	Lionel Adès (Paris)
17:25-17:30	*Discussion*	
17:30-17:45	Combination therapies for higher-risk myelodysplastic syndromes: not quite dead yet	Guillermo Garcia-Manero (Houston)
17:45-17:50	*Discussion*	
17:50-18:05	To all regulatory bodies: these should be the response criteria for higher-risk myelodysplastic syndromes!	Amer Zeidan (New Haven)
18:05-18:10	*Discussion*	
18:10-18:17	Selected brief oral communication *Carbacitabine (CAB): A Next-Generation Hypomethylating Agent with Markedly Reduced Toxicity and Superior Efficacy in High-Risk AML/MDS*	Matthias Heiss (Germany)

18:17-18:20 *Discussion*

18:20-18:50 *Panel discussion*

Sunday, October 18th, 2026

07:30-08:30 3 Simultaneous breakfast Meet the Expert sessions (Clinical)

1. Treatment of lower-risk myelodysplastic syndromes — Valeria Santini (Florence)
2. Treatment of higher-risk myelodysplastic syndromes — Mikkael Sekeres (Miami)
3. Treatment of CMML — Raphaël Itzykson (Paris)

SESSION VIII – Transplantation
Chair(s): Guillermo Garcia-Manero (Houston)

08:40-08:45	Introduction	Guillermo Garcia-Manero (Houston)
08:45-09:00	Allogeneic transplant for myelodysplastic syndromes: overview of current concepts	Nicolaus Kröger (Hamburg)
09:00-09:05	*Discussion*	
09:05-09:20	Which lower risk myelodysplastic syndromes patients should we transplant and when?	Nicolaus Kröger (Hamburg)
09:20-09:25	*Discussion*	
09:25-09:40	Is there a role for CAR-T cell therapy in MDS/AML?	Ana Alfonso Piérola (Navarra)
09:40-09:45	*Discussion*	
09:45-09:52	Selected brief oral communication *Integrated genetic and endothelial risk stratification identifies distinct outcomes after allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms*	Alejandro Avendaño Pita (Salamanca)
09:52-09:55	*Discussion*	
09:55-10:25	*Panel discussion*	
10:25-10:55	***Coffee break***	

SESSION IX – Academic clinical trials
Chair(s): Pierre Fenaux (Paris)

10:55-11:00	Introduction	Pierre Fenaux (Paris)
11:00-11:15	German, EMSCO, italian	Klaus Metzeler (Leipzig) &
11:15-11:20	*Discussion*	Valeria Santini (Florence)
11:20-11:35	French, spanish	Pierre Fenaux (Paris)
11:35-11:40	*Discussion*	
11:40-11:55	US, others	Guillermo Garcia-Manero (Houston) &
11:55-12:00	*Discussion*	Mikkael Sekeres (Miami)

12:00-12:07 Selected brief oral communication Margareta Radic Antolic (Zagreb)
The importance of detecting and reporting VUS for identifying patients at risk of developing MDS
12:07-12:10 *Discussion*

12:10-12:40 *Panel discussion*

12:40-12:50 Closing remarks
MEETING CLOSURE